Evidence map›Paper›PMID 40088473›Full record

Observational studyRevista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)2025

Association of typical and atypical antipsychotics with mortality in older adults with schizophrenia: a 5-year multicenter prospective study.

Raphaëlle Haddad, Marina Sánchez-Rico, Katayoun Rezaei, Sandra Abou Kassm, Carlos Blanco, Mark Olfson, Frédéric Limosin, Nicolas Hoertel, CSA Study Group

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raphaëlle HaddadDépartement de Psychiatrie et Addictologie de l'adulte et du sujet âgé, Hôpital Corentin-Celton, Université Paris Cité, Assistance Publique- Hôpitaux de Paris-Centre (AP-HP), Issy-les-Moulineaux, France.
Marina Sánchez-RicoDépartement de Psychiatrie et Addictologie de l'adulte et du sujet âgé, Hôpital Corentin-Celton, Université Paris Cité, Assistance Publique- Hôpitaux de Paris-Centre (AP-HP), Issy-les-Moulineaux, France.
Katayoun RezaeiDépartement de Psychiatrie et Addictologie de l'adulte et du sujet âgé, Hôpital Corentin-Celton, Université Paris Cité, Assistance Publique- Hôpitaux de Paris-Centre (AP-HP), Issy-les-Moulineaux, France.
Sandra Abou KassmDépartement de Psychiatrie, Centre Hospitalier Guillaume Régnier, Rennes, France.
Carlos BlancoDivision of Epidemiology, Services, and Prevention Research, National Institute On Drug Abuse, Bethesda, MD, USA.
Mark OlfsonDepartment of Psychiatry, Columbia University Medical Center/New York State Psychiatric Institute, New York, USA.
Frédéric LimosinDépartement de Psychiatrie et Addictologie de l'adulte et du sujet âgé, Hôpital Corentin-Celton, Université Paris Cité, Assistance Publique- Hôpitaux de Paris-Centre (AP-HP), Issy-les-Moulineaux, France. Institut de Psychiatrie et Neurosciences de Paris, L'Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche (INSERM UMR) S1266, Paris, France. Faculté de Santé, Unité de Formation et de Recherche (UFR) de Médecine, Université Paris Cité, Paris, France.
Nicolas HoertelDépartement de Psychiatrie et Addictologie de l'adulte et du sujet âgé, Hôpital Corentin-Celton, Université Paris Cité, Assistance Publique- Hôpitaux de Paris-Centre (AP-HP), Issy-les-Moulineaux, France. Institut de Psychiatrie et Neurosciences de Paris, L'Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche (INSERM UMR) S1266, Paris, France. Faculté de Santé, Unité de Formation et de Recherche (UFR) de Médecine, Université Paris Cité, Paris, France.
CSA Study Group

Funding

French Ministry of Health and Social Affairs PHRC 2008-N11-01French Ministry of Health and Social Affairs/Programme Hospitalier de Recherche Clinique PHRC 2008-N11-01French Psychiatric Congress
6 · The paper itself

Abstract

objectiveDue to the uncertainty whether atypical and typical antipsychotics have a stronger association with mortality among older people with schizophrenia, we examined the rates and causes of mortality in older adults with schizophrenia who take atypical or typical antipsychotics.

methodsIn a 5-year prospective multicenter study of patients aged = 55 years with an ICD-10 diagnosis of schizophrenia, we used a multivariable logistic regression model to examine the association between atypical vs. typical antipsychotics and mortality, adjusting for sociodemographic and clinical characteristics.

resultsOf 313 older adults with schizophrenia, the 5-year all-cause mortality rates in patients who took atypical (n=192) and typical (n=167) antipsychotics were 36.4% and 24.3%, respectively. Following adjustment, no significant differences were found in all-cause mortality (AOR = 1.56; 95%CI 0.75-3.27; p = 0.24) or causes of mortality (all p > 0.05) between medication groups. Atypical antipsychotics were significantly associated with lower overall mortality in the subpopulation with baseline Mini Mental State Examination scores < 24 (AOR = 0.24; 95%CI 0.07-0.84; p = 0.025).

conclusionAlthough atypical antipsychotics may not be associated with lower odds of overall mortality than typical antipsychotics in older people with schizophrenia, they might be associated with lower mortality among those with substantial cognitive impairment.

Indexed as

Antipsychotic AgentsSchizophreniaAgedCause of DeathFemaleHumansMaleMiddle AgedProspective StudiesSocioeconomic FactorsAntipsychotic Agentsantipsychoticsatypicalmortalityolder adultsSchizophreniatypical

Identifiers

PMID40088473
PMCPMC12815309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.